Genomic Cancer Testing


Current hospital treatment protocols rely on the assumption that patients with cancer of the same tissue type have the same underlying disease. This is why up to 75% of patients fail first line treatments.

Nantehealth (USA) puts it this way – “Oncologists use all the information available to make the best decisions for their patients. And yet, response rates for most cancer therapies remain low, with only 25% of cancer patients benefiting from the offered drug.

What if you could know more about each patient’s tumor? Could you drive up that 25%, and give your patients better outcomes?

Cancer is a complex disease, caused by a wide range of genetic mutations. These mutations can be present in many combinations that are unique to each patient, essentially making every case of cancer a rare disease.

However, each tumour has a unique genetic makeup, even amongst the same tissue type. Identification of these individual mutations is the key to developing personalised treatments for cancer patients. This is why most of our patients achieve outcomes well beyond clinical expectations.

What the new tests mean…

*No more guesswork about treatment decisions

*Better Targeted Treatments

*Fewer side effects & unnecessary suffering

*Better Healing Outcomes

In recent years our patient outcomes have improved greatly due to these new genomic, pharmacogenomic & DNA tests. The tests below are worthy of your study.


*Determine target treatments – not hit & miss.
*Indicate patient’s ability to metabolise cancer treatments.
Determine tolerance, suitability to chemotherapy or radiation treatment.
Determine tolerance, suitability to drug-based immune therapies. 
*Determine tolerance, suitability to medicines, anaesthetics
*Identify optimal nutrition plans.
Indicate best exercise for your genetic type.
Determine suitability for cannabinoid therapies.
Monitor presence of cancer, (3 months before scans will show the cancer) 

These formidable new tests lay the foundation for precision medicine, (personalised or targeted medicine). Targeted treatments generally have better outcomes and fewer side effects. The tests herald the age of minimally invasive cancer treatments & form the basis for our 5-point survivorship care plan.

Patients enrolled in our Cancer Navigation Packages are referred to world certified genomic diagnostic tests ensuring an accurate diagnosis & identification of target treatments

In the better USA hospitals, Genomic Diagnostics replace the outdated one size fits all model. No more guesswork

However; one size fits all approaches are still common in…

*Our hospitals – AU & NZ: This is the Gold Standard of Cancer Care. Hospitals are limited by finances, pharmaceutical companies, politics & insurance protocols.

*Supplements, super-foods or extreme diet approaches erroneously assume patients are genetically the same & can all metabolise essential ingredients & constituents similarly.

*Generic advice from Dr Google, family, friends, workmates is by nature, one size fits all, and may do more harm than good, can even cause or accelerate cancer.

Genome Mag – understanding the outdated one size fits all approach:

“Most often today, your treatment plan isn’t about you specifically. It’s what doctors would give to anyone with the same condition — your neighbour, the hot dog vendor, or the prime minister of Bangladesh. Most cancer medicine revolves around “standards of care,” that is providing the best courses of prevention or treatment for the average person on the street.

With breast cancer, for example, those standards mean self-exams and mammograms after a set age and the usual chemotherapy, surgery to treat a tumour if one is found.If the first treatment doesn’t work, doctors and patients move on to the next one and the next. It’s trial and error, with life on the line.

But each cancer in each person has its own genetic makeup – each tumour is a unique character with unique tendencies and vulnerabilities. In some cases, the current standard of care may be the safest, most sensible option, but it’s also one size fits all. 

Sometimes that’s sufficient, but not always.” Genome Mag

Australian & New Zealand Cancer Patients are missing out on a second chance at life compared to other OECD countries

Austtralia slow to get medical drugs